Vesugen — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Vesugen

Also known as: Vezugen, KED peptide, Lys-Glu-Asp, T-38, tripeptide T-38

Short regulatory tripeptide / cytogen / geroprotector

Research chemicalLast updated: October 31, 2026Based on 21 peer-reviewed studies

What it is

Vesugen is a short peptide studied for vascular protection, anti-aging, and skin regeneration, with research suggesting it supports gene activity in blood vessel and nerve cells. It works by influencing gene expression in target tissues to maintain or restore function. No FDA-approved use; primarily studied in Russian longevity research.

The scientific side

Vesugen (Lys-Glu-Asp; KED) is a short tripeptide that appears to exert its biological effects primarily through epigenetic and transcriptional regulation. Studies report that it interacts with promoter regions of target genes (including MKI67, the gene encoding Ki-67, and the 5-tryptophan hydroxylase gene) via molecular docking complementarity, modulating gene expression at nanomolar concentrations. Reported molecular effects include: stimulation of proliferation-associated Ki-67 expression and inhibition of proapoptotic p53 in vascular endothelial and other cells; normalization of endothelin-1 expression and restoration of connexin-mediated cell interactions in endothelium; upregulation of sirtuin-1 involved in DNA repair; stimulation of IGF1 gene expression and inhibition of FOXO1 in mesenchymal stem cells; tissue-specific induction of differentiation markers CXCL12 and WEGC1 in prostatic fibroblasts; stimulation of serotonin synthesis in brain cortex cells; and inhibition of MMP-9 while enhancing Ki-67 and CD98hc in aging skin fibroblasts. In neurons and induced neurons, KED promotes dendritic arborization and reduces oxidative DNA damage. The peptide also demonstrated anti-atherosclerotic molecular activity by reducing E-selectin synthesis and normalizing endothelin-1 in vascular cells.

Class: Short regulatory tripeptide / cytogen / geroprotector

Administration & storage

Administration
Intraperitoneal injection — used in animal study of pancreatic function (PMID: 18942368)Oral administration — reported for KED in elderly humans with functional CNS disorders (PMID: 34173097)
Storage
No storage conditions for Vesugen are described in any of the reviewed abstracts.
Cautions
Prooxidant activity was detected via chemiluminescence in a human study of Vesugen and Pinealon as geroprotectors.,Decrease of CD34+ positive hematopoietic polypotent cells in blood was observed, suggesting significant inhibition of hemopoiesis in the study population.,No effect on chromatin condensation was observed, interpreted by the authors as safety at the nuclear genetic level, though the authors noted this property should be studied further.,Human pharmacokinetic data (absorption, distribution, metabolism, excretion) are not reported in any reviewed abstract — clinical safety profile is incompletely characterized.,Sterile technique is essential for any injectable preparation to prevent contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification